Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Pacira Pharn Form 4 June 08, 201	naceuticals, Inc.					
FORM	1			OMB API	PROVAL	
	UNITED STAT	Washington, D.C. 20549			3235-0287	
Check th if no long subject to Section 1 Form 4 c Form 5 obligatio may con <i>See</i> Instr 1(b).	section 17(a) of the	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section				
(Print or Type 1	Responses)					
1. Name and A Kronenfeld	Address of Reporting Person <u>*</u> Mark A.	2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]	Issuer Pharmaceuticals, Inc. [PCRX]			
(Last)	(First) (Middle)	3. Date of Earliest Transaction	(Check	c all applicable)		
	A CEUTICALS, INC., 5 VAY, SUITE 300	(Month/Day/Year) 06/06/2016				
	(Street)	4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check			
PARSIPPA	NY, NJ 07054	Filed(Month/Day/Year)	y/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State) (Zip)	Table I - Non-Derivative Securities Ac	auired. Disposed of.	or Beneficially	Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. D (Month/Day/Year) Execu any (Mont	eemed 3. 4. Securities Acquired tion Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) h/Day/Year) (Instr. 8) (A) or Code V Amount (D) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of	
Common Stock	06/06/2016	$S_{(1)}^{(1)} 900_{(2)}^{(2)} D $ 46.95	2,950	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Other

Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships			
F F	Director	r 10% Owner	Officer		
Kronenfeld Mark A. C/O PACIRA PHARMACEUTICALS, I 5 SYLVAN WAY, SUITE 300 PARSIPPANY, NJ 07054	NC. X				
Signatures					
/s/ James Scibetta, Attorney-in-Fact	06/08/2016				

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in (1) accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- (2) Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

Date

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.